DTC患者TSH抑制治疗致骨质疏松症的研究进展  

Research progress of osteoporosis caused by TSH suppression therapy in DTC patients

作　　者：梁钰婷 陆克义[1] 晋建华[1] Liang Yuting;Lu Keyi;Jin Jianhua(Department of Nuclear Medicine,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院核医学科,太原030001

出　　处：《国际放射医学核医学杂志》2022年第12期749-754,共6页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：促甲状腺激素(TSH)抑制治疗是分化型甲状腺癌(DTC)治疗的主要方法之一,其能够有效降低DTC的复发和转移风险。TSH抑制治疗可加速骨转换、导致骨密度降低、骨微结构恶化,从而增加骨质疏松症及脆性骨折的发生风险,严重影响DTC患者的生存率和生活质量。笔者就近年来DTC患者TSH抑制治疗致骨质疏松症的研究进展作一综述,以期为DTC患者制定个体化的治疗方案提供参考。As one of the main treatments of differentiated thyroid cancer(DTC),thyroid-stimulating hormone(TSH)suppression therapy reduces the risk of recurrence and metastasis of DTC.It also accelerates bone turnover,leads to decreased bone density and deterioration of bone microstructure,increases the risk of osteoporosis and fragility fractures,thus affecting the survival rate and quality of life of DTC patients.This article reviews the recent research progress of osteoporosis caused by TSH suppression therapy in DTC patients to provide a reference for the development of individualized treatment strategies for DTC patients.

关 键 词：促甲状腺素 骨质疏松 骨密度 抑制治疗 分化型甲状腺癌 

分 类 号：R736.1[医药卫生—肿瘤]